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Purpose: Several international committees involved in establishing standards of care have recommended that patients undergoing 
surgery for bladder outlet obstruction should be assessed with patient reported outcomes (PRO). The Patient Global Impression of 
Improvement (PGI-I) is an instrument designed to measure a patients interpretation of symptom changes following intervention. The 
objective of this study was to validate the PGI-I as a PRO assessment following surgery for bladder outflow obstruction (BOO) in men 
with benign prostatic hyperplasia (BPH). 
Methods: Men undergoing photoselective vaporisation of the prostate were followed prospectively. Pre- and postoperative 
International Prostate Symptom Score (IPSS), Quality of life (QoL) index, peak urinary flow (Qmax), and postvoid residual (PVR) 
assessments were done. The PGI-I was conducted and correlated at 3 months postoperatively to changes in IPSS, QoL, Qmax, and PVR. 
Results: One hundred and sixty-six consecutive patients were included. Following surgery, IPSS and QoL improved by 11 and 2.4 
points (P<0.0001). PGI-I was found to correlate with postoperative changes in IPSS and QoL (Pearson correlation, 0.47 and 0.58, 
respectively; P<0.0001). 
Conclusions: This is the first study to validate the PGI-I as a PRO measure to surgery for BOO. This suggests a potential for the PGI-I 
to be used to assess surgical therapies for BPH and may be a valuable addition for measuring outcomes in clinical trials evaluating 
surgical interventions for BPH. 
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INTRODUCTION
Lower urinary tract symptoms (LUTS) is a common condi-
tion in men with a prevalence of bothersome symptoms re-
ported in 30%–50% [1,2]. LUTS suggestive of benign prostatic 
hypertrophy (BPH) is associated with a lower level of overall 
health related quality of life (HRQL) [3-5]. HRQL decreases as 
severity of LUTS increase [4,5]. Currently treatment success 
for this condition is limited to comparing symptoms scores 
and isolated quality of life (QoL) indexes. Several international 
committees in charge of establishing standards for measuring 
outcomes following intervention for LUTS however have rec-
ommended documenting the patients, self-reported, impact 
of treatment [6,7]. A patient’s perspective of clinical impact 
and treatment benefits can be recorded in questionnaires 
called patient reported outcomes (PROs).
 Currently, there are a range of validated questionnaires 
assessing symptoms and QoL for men with LUTS, the most 
recognised of which is the International Prostate Symptom 
Score (IPSS) also called the American Urological Association 




vational study which recruited men with significant LUTS 
whom underwent photoselective vaporization of the prostate 
(PVP), using the 120 W Greenlight laser (American Medical 
Systems, Minnetonka, MN, USA). 
 The indications for surgery were consistent with those de-
scribed by both the European Association of Urology and AUA 
guidelines [11,12]. Once identified as candidates for surgery, 
the men had their flow rate (Qmax) and postvoid residuals 
(PVRs) measured by uroflowmetry and bladder scanner. Their 
preoperative IPSS and QoL scores were also recorded at this 
time. Preoperatively, prostate size was determined by transrec-
tal ultrasound (TRUS) assessment using the ellipsoid method.
 The men subsequently underwent greenlight laser prosta-
tectomy using the 120 W lithium triborate laser. 
 Men were reviewed at both 6 weeks and 3 months. It was 
at the 3 month review, that the men were reassessed with 
the same measures but with the addition of the PGI-I. Three 
months was chosen as the best assessment point for two 
reasons. Firstly, it is at 3 months when postoperative, healing 
symptoms would have settled for the vast majority of men 
(dysuria, urgency, frequency, etc.), and men can be regarded 
as having reached treatment baseline. Secondly it is close 
enough for most men to maintain reasonable recall of their 
preoperative symptoms and more accurately assess how their 
symptoms have changed with treatment.
 The IPSS, QoL, Qmax, and PVR results were compared 
from baseline to the 3-month follow-up using paired t-test 
and Wilcoxon signed rank test. The validity of the PGI-I was 
assessed by correlating the PGI-I response to changes in the 
other assessment tools. Pearson coefficient was used for 
correlations. Statistical significance was concluded when 
P≤ 0.05. Statistical analysis was performed with SPSS Statstics 
GradPac ver. 18 (IBM Co., Amonk, NY, USA).
RESULTS
One hundred sixty-six consecutive patients who underwent 
PVP were included. Thirty-two patients were excluded due to 
incomplete follow-up. Incomplete follow-up occurred in 19 
patients because the PGI-I score was not recorded (reasons 
unclear), in a further 12 patients because they did not attend 
follow-up and one died prior to follow-up.  
 Twenty-four patients were in acute retention preoperative, 
with 19 having an indwelling catheter and 5 doing intermit-
tent self-catheterisation. When presenting changes in flow 
rate and PVR and when correlating these results with PGI-I, 
patients in acute retention were excluded.
 Mean age at surgery was 67 years (Table 2).  Mean TRUS 
(AUA) BPH symptom score questionnaire. This question-
naire includes five questions on voiding symptoms (noc-
turia, frequency, etc.) and a single question on QoL. These 
questionnaires are aimed at assessing a patient’s symptoms 
at a particular point in time. Changes in scores overtime are 
used to assess outcomes following intervention but they are 
not designed to assess the patient’s perception of changes in 
symptoms postintervention.  
 PRO assessments are designed specifically to assess a pa-
tient’s perception of changes following treatment. A global 
index is a PRO assessment, which ranks patients change 
in symptom following intervention, in a way that is easy to 
use, compared and interpret. A global scale gives an overall 
appraisal of a patient’s perception of change following in-
tervention. Currently, no global assessment instrument has 
been validated for assessing outcomes in the management of 
LUTS.  The Patient Global Impression of Improvement (PGI-
I) index is a possible candidate for this role. The PGI-I scale 
was originally modelled after psycho-pharmacological scales 
described in 1976 (Clinical Global Impression) [8]. The Clini-
cal Global Impression-Improvement (CGI-I) scale is a 7-point 
scale that requires the clinician to assess how much the pa-
tient’s illness has improved or worsened relative baseline. The 
PGI-I scale used is the same but is completed by the patient 
(Table 1). It has been validated for use in female patients 
following intervention for both urinary incontinence and 
prolapse [9,10]. It has also been demonstrated to have excel-
lent test-retest reliability [10]. Yalcin and Bump [9] altered the 
stem of the questionnaire for their patients with stress urinary 
incontinence but maintaining the response options. This 
study used their version of the PGI-I.
 The aim of this study was to validate the use of the PGI-I 
in men following surgical treatment of LUTS by correlating it 
with other outcome assessment measures. 
MATERIALS AND METHODS
This project was part of a prospective, longitudinal, obser-
Table 1. Patient Global Impression of Improvement 
Check the one number that best describes how your urinary tract con-
dition is now compared with how it was before your operation
1 Very much better
2 Much better
3 A little better
4 No change
5 A little worse
6 Much worse
7 Very much worse




changes in Qmax (P= 0.56). 
 Changes in Qmax did not correlate with changes in QoL 
(P= 0.91) but showed a weak correlation with changes in 
IPSS (Pearson coefficient = 0.19, P= 0.53). Changes in PVR 
did correlate with changes in QoL (Pearson coefficient = 0.21, 
P= 0.036) and changes in IPSS (Pearson coefficient = 0.24, 
P= 0.019). 
DISCUSSION
After an operation, a patient will form an opinion as to 
whether or not the procedure was a success, that is, did it ‘cure’ 
or improve their symptoms. Unfortunately there is a paucity 
of data documenting these opinions following surgical inter-
vention for LUTS, especially for PVP. This absence of informa-
tion results directly from the fact that we have no reliable way 
of recording this information. 
 A surgeon assesses if treatment for BPH was successfully 
by measuring common symptom and sign parameters, for 
example flow rate and IPSS scores. Failure to record improve-
ment in these parameters is usually regarded as treatment 
failure or a result from the development of treatment com-
plications. Recognised complications following PVP include 
urethral stricture, bladder neck contractor and detrusor over-
activity, all of which frequently impact on standard postop-
erative assessment tools. 
 A patient impression of success however may also be 
influenced by other, unmeasured factors. These include 
volume was 45 mL. The average preoperative IPSS score 
was 20 (range, 2–35), with 96% of patients having a score ≥ 8. 
Mean preoperative QoL score, Qmax, and PVR were 4.4, 8 
mL/sec, and 169 mL, respectively (Table 2). 
 At 3-month postoperative review the IPSS and QoL scores 
improved by an average of 11 and 2.4, to means of 9 and 2 re-
spectively (P< 0.0001) (Table 3). Qmax significant improved 
by an average of 14 mL/sec (P< 0.0001), while PVR decreased 
to a mean of 36 mL. 
 The average PGI-I score was 2 (much better). The highest 
score was 6 (much worse). Overall 96% responded 3 or bet-
ter (Table 4). The other 4% reported their symptoms were 
unchanged or worse. The patient who responded with a score 
of 6 reported this outcome despite showing improvement in 
both IPSS and Qmax.  
 The mean change in IPSS score was 11 (standard deviation 
[SD], 8), QoL score was 2.4 (SD, 1.9), Qmax was 14 mL/sec 
(SD, 10), and PVR was 133 mL (SD, 160). All of these changes 
were statistically significant (Table 3). 
 Pearson coefficient was used to correlate changes in results 
to the PGI-I score. The PGI-I score correlated strongly with 
changes in IPSS and QoL, with Pearson correlations of 0.47 
and 0.58, respectively (P< 0.0001). A less but still significant 
correlation was observed with PVR, with a Pearson correla-
tion of 0.21 (P= 0.041) (Table 5). It did not correlate with 







PVR (mL) 169±161 
PV (mL) 45±33
PVP, photoselective vaporisation of the prostate; SD, standard devia-
tion; IPSS, International Prostate Symptom Score; QoL, quality of life; 
Qmax, peak urinary flow; PVR, postvoid residual; PV, prostate volume. 








IPSS 20 9 11±0.70 <0.0001
QoL index 4.4 2 2.4±0.17 <0.0001
Qmax 
   (mL/sec)
8 22 –14±0.96 <0.0001
PVR (mL) 169 36 133±16 <0.0001
PVP, photoselective vaporisation of the prostate; SEM, standard error of 
the mean; IPSS, International Prostate Symptom Score; QoL, quality of 
life; Qmax, peak urinary flow; PVR, postvoid residual.
Table 4. PGI-I scores post PVP







PGI-I, Patient Global Impression of Improvement; PVP, photoselective 
vaporisation of the prostate.
Table 5. Correlation of PGI-I to change in IPSS, QoL, Qmax, and 
PVR 3 months following PVP
Variable Mean change Pearson correlation P-value
IPSS 11 0.47 <0.0001
QoL index 2.4 0.58 <0.0001
Qmax (mL/sec) –14 –0.06 0.560
PVR (mL) 133 0.21 0.041
PGI-I, Patient Global Impression of Improvement; IPSS, International 
Prostate Symptom Score; QoL, quality of life; Qmax, peak urinary flow; 
PVR, postvoid residual.




expectations regarding outcome, which can be shaped by 
previous personal experiences, experiences of friends and 
relatives and also the attitude of the clinician. It may also be 
influenced by the development of new symptoms not asked 
about in common questionnaires (incontinence and sexual 
dysfunction). Also long-term follow-up studies have revealed 
that patients expect surgery to help them achieve a specific 
goal and reaching this goal impacts on their opinion of suc-
cessful treatment [13,14]. 
 Consequently the concept of ‘cure’ should not be limited 
to a surgeon assessment of changes in symptom scores and 
objective measures. The patient’s self-reported impression 
of treatment success is equally as important. PRO assess-
ments or PRO questionnaires, aim at documenting a patient’s 
impression of treatment success therefore give insight into 
whether their goal for treatment was achieved. 
 QoL assessment indications a patient’s current global sta-
tus at a particular point in time. Improvement in QoL is fre-
quently used as an indicator of effective treatment however 
there is little evidence to clarify what constitutes a significant 
or meaningful change in QoL scores [15]. For example, im-
provement in QoL, may come simply from a patient becom-
ing more accepting of their urinary condition rather than any 
change in voiding behaviour occurring. 
 A PRO is an objective assessment of the patient’s subjec-
tive experience. PROs represent a clinical review of symptom 
impact and treatment benefit from a patient’s perspective. 
This can be measured independent of changes in symptoms 
scores and QoL indexes. The advantage of using a global in-
dex is that it provides a single best measure of change from 
the individual’s perspective. A global index can assess clini-
cally meaningful change by taking into account more infor-
mation than that reflected in the IPSS scores and QoL Index.  
 PROs are not just beneficial for the individual patient. 
Global assessment of treatment outcomes can be used for 
quality assurance. Clinical governance is a systematic ap-
proach to maintaining and improving the quality of patient 
care within a health system. PROs can be used to efficiently 
assess patient outcomes and rapidly signal if a deviation is oc-
curring. Since these questionnaires are nonspecific, they have 
the ability to incorporate all factors which may be influencing 
patient perceived outcomes. When deviations are identified, 
early intervention can occur to help identify the cause and 
minimise the impact on patient outcomes, thus maintaining 
appropriate quality of care. 
 Unfortunately, there is currently no validated, easy to ad-
minister, PRO to assess outcome following surgery for BPH 
in patients with LUTS. The PGI-I was identified as a possible 
candidate.
 The PGI-I scale was originally modelled after the 1976 psy-
cho-pharmacological scale used in psychiatry called the CGI-
I. The CGI-I is a 7-point scale, completed by the clinician, who 
rates how much they perceive a patient’s illness has changed 
following intervention. Later, the perspective of the CGI-I was 
to that of the patient, making it the PGI-I scale. This modified 
scale was then adopted to assess patient outcomes in other 
areas, including outcomes following hearing aid fitting and to 
evaluate the efficacy of therapy in the management of neuro-
pathic pain. 
 In 2003, Yalcin and Bump [9] modified the stem question, 
making it suitable for patients with lower urinary tract condi-
tions. They then established its validity in assessing female 
patients following surgery for stress urinary incontinence. 
They found the PGI-I to be a simple to administer and inter-
pret questionnaire. Their PGI-I had the potential to be utilised 
as an alternative way of examining patient expectations fol-
lowing treatment for LUTS and allows objective assessment 
of a subjective phenomenon. 
 This study was aimed at assessing the validity of the PGI-I 
as a potential PRO for men undergoing PVP for LUTs. In order 
to assess the suitability of a certain PRO to assess outcomes 
following a particular treatment, it is critical to correlate it to 
known outcome success measures. The validity of the PGI-I 
for assessing outcomes following PVP for BPH therefore was 
tested by correlating it to the urinary parameters usually mea-
sured following surgery.
 This study found that the PGI-I did correlate significantly 
with subjective urinary measures, particularly with improve-
ment in IPSS and QoL scores. The mean improvement in 
IPSS was 11, and this correlated with a PGI-I score of 2: much 
improved. The mean QoL score also improved an average of 
2 points, with most patients now scoring a total of 2: mostly 
satisfied with their urinary condition. Therefore an improve-
ment in overall symptoms correlated significantly with pa-
tients reporting a positive outcome. 
 The PGI-I however did not correlate particularly well with 
changes in objective measures, in this case Qmax and PVR. 
This was observed despite the fact that improvement in Qmax 
and PVR did correlated with improvement in IPSS score. This 
is possibly a reflection of the fact that the improvement in 
Qmax and PVR is more likely to improve some of the urinary 
parameters measured by the IPSS (straining and intermitten-
cy) compared to others (nocturia and frequency). This means 
that improvement in Qmax and PVR can lead to an overall 
reduction in IPSS score by decreasing some urinary param-
eters while others remain unchanged. If the unchanged pa-




rameters (nocturia and frequency) are the ones that were the 
most bothersome to the patient then, understandably, this 
will be reflected in the PGI-I score. It would be valuable to see 
if there is a relationship between individual measure in the 
IPSS questionnaire and the PGI-I. Unfortunately, in this study 
only the overall IPSS score was recorded, therefore it is not 
possible to make this comparison. This study however does 
highlight the need for a PRO measure in addition to changes 
in symptom score.
 This study was also not able to assess if the PGI-I score cor-
related with development of or changes with, urinary or other 
parameters not measured in the IPSS score. These param-
eters include incontinence, dysuria and erectile function. It 
was interesting to observe that the one patient who respond-
ed with a PGI-I score of 6 (much worse) had a measured im-
provement in both IPSS and Qmax results. This suggests that 
the patient experienced a deterioration or development of 
symptoms not recorded in the IPSS questionnaire. This is an 
area that warrants investigation in future studies. 
 In conclusion, PROs following treatment intervention for 
LUTs due to BPH are proving to be an important, indepen-
dent measure of treatment success. Currently there is little 
data to guide us toward an appropriate PRO to use in patients 
undergoing endoscopic prostatectomy. The PGI-I, a known 
PRO, has been previously validated for use in women follow-
ing surgery for prolapse and stress urinary incontinence. This 
study helps support the use of the PGI-I as an assessment 
tool following PVP for BPH. We successfully demonstrated its 
validity in this setting by identifying its strong correlation with 
changes in the IPSS score and QoL index. In addition, since 
the PGI-I is easy to administer and interpret, it has the poten-
tial to be a valuable addition, not only in clinical practice, but 
also in trials, to help compare interventions in the manage-
ment of LUTS.
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